A. Baur & Co. Ltd, also known as Baurs, entered a partnership with GSK recently to distribute the multinational pharmaceutical companys prescription medicines and vaccines in Sri Lanka.
During the latter part of last year, GSK decided to wind down its commercial business in Sri Lanka.
With this new alliance, Baurs and GSK reaffirm their unwavering commitment to the people of the country and ensure patients have uninterrupted access to GSK’s safe, effectiveand high-quality medications.
A ceremony was held at the the Shangri-La hotel recently to mark the signing of the agreement.
Baurs Managing Director/CEO Rolf Blaser andGSKExecutive Director/Chief Financial Officer and Country Manager, Sri Lanka and the Maldives, Manoj Jayawardena spoke. Baurs Director Healthcare, Nishantha Weerasinghe and Director Baur Life Sciences, Gehan Seneviratne, the board, project teams, and HoDs of Baurs and GSK Sri Lanka were also present.
GSK’s portfolio of science, medicine, R&D, and innovation will continue to be available to doctors and patients through this partnership.
Through its expansive distribution and robust marketing competencies, the company hopes to further enhance product availability across the island, complying with industry standards in cold chain management.
GSK is prioritising research into vaccines and medicines across four core therapeutic areas: infectious diseases, HIV, oncology, and immunology. At the heart of enabling this work is its R&D focus on the science of the immune system, human genetics, and advanced technologies, a company spokesman said.